Grifols, S.A. (BME:GRF)

Spain flag Spain · Delayed Price · Currency is EUR
9.47
-0.02 (-0.25%)
May 30, 2025, 5:35 PM CET
5.11%
Market Cap 5.90B
Revenue (ttm) 7.37B
Net Income (ttm) 195.23M
Shares Out 680.41M
EPS (ttm) 0.29
PE Ratio 33.18
Forward PE 11.23
Dividend n/a
Ex-Dividend Date n/a
Volume 2,221,802
Average Volume 2,156,800
Open 9.53
Previous Close 9.49
Day's Range 9.42 - 9.55
52-Week Range 7.32 - 11.35
Beta 0.93
RSI 64.24
Earnings Date May 5, 2025

About Grifols

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A an... [Read more]

Sector Healthcare
Founded 1909
Employees 23,833
Stock Exchange Madrid Stock Exchange
Ticker Symbol GRF
Full Company Profile

Financial Performance

In 2024, Grifols's revenue was 7.21 billion, an increase of 9.41% compared to the previous year's 6.59 billion. Earnings were 156.92 million, an increase of 270.81%.

Financial Statements

News

US court finds enough evidence to proceed with Grifols lawsuit against Gotham City

A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company Grifols against short seller Gotham City Research, Grifols said in a statement on...

9 hours ago - Reuters

Grifols S.A. reports Q1 results

17 days ago - Seeking Alpha

Grifols says on course to meet 2025 outlook as net profit triples

Grifols's net profit almost tripled from a year earlier, which the Spanish drugmaker said reinforced its confidence in meeting its full-year guidance.

17 days ago - Reuters

Grifols: A Market Setback Turns Into Buying Opportunity

Despite the market punishing Grifols, we believe that this presents a buying opportunity. Click here for our investment thesis on GRFS stock.

5 weeks ago - Seeking Alpha

White Falcon Capital Q1 2025 Partner's Letter

White Falcon Capital's Q1 2025 letter discusses their take on tariffs, provides a portfolio update, and presents an investment thesis on Grifols SA. Click here to read more.

5 weeks ago - Seeking Alpha

IBL International collaborates with Grifols on advanced biomarker panels

MÄNNEDORF, Switzerland--(BUSINESS WIRE)--IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a strategic partnership with Grifols, a...

7 weeks ago - Business Wire

Brookfield said to revive talks on potential Grifols offer

Brookfield Asset Management Ltd. has revived talks with Grifols SA’s main shareholder about a potential offer for the Spanish blood-plasma company following a failed attempt last year, according to pe...

2 months ago - BNN Bloomberg

Grifols (GRFS) Shares Surge Amid Renewed Brookfield Acquisition Talks

Grifols (GRFS) Shares Surge Amid Renewed Brookfield Acquisition Talks

2 months ago - GuruFocus

Brookfield resumes Grifols takeover talks, El Confidencial reports

Canadian investment fund Brookfield has resumed talks on a potential takeover of Spanish pharmaceuticals company Grifols four months after a previous attempt fell through, news website El Confidencial...

2 months ago - Reuters

Grifols expects to boost revenue and free cash flow, shares soar

Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the coming years as it aims to leave behind a tumultuous 2024 when it lost ...

3 months ago - Reuters

Grifols SA (GIFLF) (Q4 2024) Earnings Call Highlights: Record Revenues and Strategic ...

Grifols SA (GIFLF) (Q4 2024) Earnings Call Highlights: Record Revenues and Strategic Advancements Amid Challenges

3 months ago - GuruFocus

Full Year 2024 Grifols SA Earnings Call Transcript

Full Year 2024 Grifols SA Earnings Call Transcript

3 months ago - GuruFocus

Grifols' sales rise over 10% in 2024, above target

Spanish drugmaker Grifols reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7.21 billion euros, up 10.2% from a year earlier and above its target for 7%...

3 months ago - Reuters

Permian Investment Partners, LP Increases Stake in Grifols SA

Permian Investment Partners, LP Increases Stake in Grifols SA

3 months ago - GuruFocus

Blood Plasma Derivatives Market Insights and Forecast 2025-2030 - Grifols, SK Plasma, and Fusion Health Care Lead the Competition

Rising Incidence of Hemophilia, Immunological Disorders, and the Growing Number of Surgical Procedures Worldwide is Driving Growth, at a CAGR of ~9% Rising Incidence of Hemophilia, Immunological Disor...

4 months ago - GlobeNewsWire

Grifols SA (GRFS) Partners with Michael J. Fox Foundation to Advance Parkinson's Disease Research

Grifols SA (GRFS) Partners with Michael J. Fox Foundation to Advance Parkinson's Disease Research

4 months ago - GuruFocus

Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease

BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced it h...

4 months ago - GlobeNewsWire

Mason Capital complains about Grifols' transparency to Spanish regulator

U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding more transparency from the embattled pharmaceutical company Grifols.

4 months ago - Reuters